WAP
PTCT icon

Wealthcare Advisory Partners’s PTC Therapeutics PTCT Stock Holding History

Wealthcare Advisory Partners’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-390
Closed -$18K – 1525
2021
Q1 		$18K Buy
+390
New +$23.2K ﹤0.01% 1241

Other funds holding PTCT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Wealthcare Advisory Partners's PTCT Position: Q2 2021 in Review

Wealthcare Advisory Partners sold out of PTC Therapeutics (PTCT) in Q2 2021, closing a stake of 390 shares — an estimated $18K sold.

Wealthcare Advisory Partners first reported a position in PTCT in Q1 2021 and held it in 1 quarter. The position peaked at $18K in Q1 2021. 182 funds tracked by Wall St. Rank hold PTCT as of Q2 2021.

  • Wealthcare Advisory Partners reported no remaining PTC Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Wealthcare Advisory Partners sold 390 PTC Therapeutics shares in Q2 2021, an estimated $18K.
  • Wealthcare Advisory Partners first reported a position in PTC Therapeutics in Q1 2021 and held it in 1 quarter.
  • Wealthcare Advisory Partners's PTC Therapeutics position peaked at $18K in Q1 2021.
  • 182 funds tracked by Wall St. Rank held PTC Therapeutics as of Q2 2021.

Based on Wealthcare Advisory Partners's 13F filing for Q2 2021, filed 16 Aug 2021.